CN117362305A - 9-ing-41的固体形式 - Google Patents

9-ing-41的固体形式 Download PDF

Info

Publication number
CN117362305A
CN117362305A CN202311213594.XA CN202311213594A CN117362305A CN 117362305 A CN117362305 A CN 117362305A CN 202311213594 A CN202311213594 A CN 202311213594A CN 117362305 A CN117362305 A CN 117362305A
Authority
CN
China
Prior art keywords
ing
solvate
degrees
xrpd
solid form
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202311213594.XA
Other languages
English (en)
Chinese (zh)
Inventor
张亚民
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Kinesitherapy Co
Original Assignee
Kinesitherapy Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=63405430&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CN117362305(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Kinesitherapy Co filed Critical Kinesitherapy Co
Publication of CN117362305A publication Critical patent/CN117362305A/zh
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C07D491/056—Ortho-condensed systems with two or more oxygen atoms as ring hetero atoms in the oxygen-containing ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicinal Preparation (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
CN202311213594.XA 2017-08-11 2018-08-10 9-ing-41的固体形式 Pending CN117362305A (zh)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201762544277P 2017-08-11 2017-08-11
US62/544,277 2017-08-11
PCT/US2018/046203 WO2019032958A1 (en) 2017-08-11 2018-08-10 SOLID FORMS OF 3- (5-FLUOROBENZOFURAN-3-YL) -4- (5-METHYL-5H [1,3] DIOXOLO [4,5-F] INDOL-7-YL) PYRROLE-2,5-DIONE
CN201880059690.4A CN111247153B (zh) 2017-08-11 2018-08-10 3-(5-氟苯并呋喃-3-基)-4-(5-甲基-5H-[1,3]间二氧杂环戊烯并[4,5-f]吲哚-7-基)吡咯-2,5-二酮的固体形式

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
CN201880059690.4A Division CN111247153B (zh) 2017-08-11 2018-08-10 3-(5-氟苯并呋喃-3-基)-4-(5-甲基-5H-[1,3]间二氧杂环戊烯并[4,5-f]吲哚-7-基)吡咯-2,5-二酮的固体形式

Publications (1)

Publication Number Publication Date
CN117362305A true CN117362305A (zh) 2024-01-09

Family

ID=63405430

Family Applications (2)

Application Number Title Priority Date Filing Date
CN202311213594.XA Pending CN117362305A (zh) 2017-08-11 2018-08-10 9-ing-41的固体形式
CN201880059690.4A Active CN111247153B (zh) 2017-08-11 2018-08-10 3-(5-氟苯并呋喃-3-基)-4-(5-甲基-5H-[1,3]间二氧杂环戊烯并[4,5-f]吲哚-7-基)吡咯-2,5-二酮的固体形式

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN201880059690.4A Active CN111247153B (zh) 2017-08-11 2018-08-10 3-(5-氟苯并呋喃-3-基)-4-(5-甲基-5H-[1,3]间二氧杂环戊烯并[4,5-f]吲哚-7-基)吡咯-2,5-二酮的固体形式

Country Status (16)

Country Link
US (3) US11136334B2 (cg-RX-API-DMAC7.html)
EP (1) EP3665176B1 (cg-RX-API-DMAC7.html)
JP (3) JP7424639B2 (cg-RX-API-DMAC7.html)
KR (3) KR20250070131A (cg-RX-API-DMAC7.html)
CN (2) CN117362305A (cg-RX-API-DMAC7.html)
AU (3) AU2018313259B2 (cg-RX-API-DMAC7.html)
BR (1) BR112020002892A2 (cg-RX-API-DMAC7.html)
CA (1) CA3072240A1 (cg-RX-API-DMAC7.html)
DK (1) DK3665176T3 (cg-RX-API-DMAC7.html)
ES (1) ES2974328T3 (cg-RX-API-DMAC7.html)
FI (1) FI3665176T3 (cg-RX-API-DMAC7.html)
IL (2) IL272556B2 (cg-RX-API-DMAC7.html)
MX (3) MX2020001547A (cg-RX-API-DMAC7.html)
PL (1) PL3665176T3 (cg-RX-API-DMAC7.html)
PT (1) PT3665176T (cg-RX-API-DMAC7.html)
WO (1) WO2019032958A1 (cg-RX-API-DMAC7.html)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11407759B2 (en) * 2017-10-16 2022-08-09 Actuate Therapeutics Inc. Solid forms of 3-(5-fluorobenzofuran-3-yl)-4-(5-methyl-5H-[1,3]dioxolo[4,5-f]indol-7-yl)pyrrole-2,5-dione
KR20210038429A (ko) * 2018-05-17 2021-04-07 액투에이트 테라퓨틱스 인크. 글리코겐 신타제 키나제 3 형태 베타 억제제를 사용한 특발성 폐 섬유증의 치료
CA3251821A1 (en) * 2022-06-27 2024-01-04 Actuate Therapeutics, Inc. ORAL DOSAGE FORMS OF ELRAGLUSIB

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008077138A1 (en) * 2006-12-19 2008-06-26 The Board Of Trustees Of The University Of Illinois 3-benzofuranyl-4-indolyl maleimides as potent gsk3 inhibitors for neurogenerative disorders

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2013515737A (ja) 2009-12-23 2013-05-09 アークル インコーポレイテッド 精製されたピロロキノリニル−ピロリジン−2,5−ジオン組成物ならびにその調製方法および使用方法

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008077138A1 (en) * 2006-12-19 2008-06-26 The Board Of Trustees Of The University Of Illinois 3-benzofuranyl-4-indolyl maleimides as potent gsk3 inhibitors for neurogenerative disorders

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
IRINA N. GAISINA ET AL.: ""From a Natural Product Lead to the Identification of Potent and Selective Benzofuran-3-yl-(indol-3-yl)maleimides as Glycogen Synthase Kinase 3β Inhibitors That Suppress Proliferation and Survival of Pancreatic Cancer Cells"", 《JOURNAL OF MEDICINAL CHEMISTRY》, vol. 52, no. 7, 16 March 2009 (2009-03-16), pages 1853, XP055516483, DOI: 10.1021/jm801317h *
KRISHNENDU PAL ET AL.: ""Inhibition of GSK-3 Induces Differentiation and Impaired Glucose Metabolism in Renal Cancer"", 《MOLECULAR CANCER THERAPEUTICS》, vol. 13, no. 2, 10 December 2013 (2013-12-10), pages 285 - 298 *
吕扬 等: "《晶型药物》", 31 December 2009, 人民卫生出版社, pages: 115 - 116 *

Also Published As

Publication number Publication date
DK3665176T3 (da) 2024-03-25
WO2019032958A1 (en) 2019-02-14
US11136334B2 (en) 2021-10-05
US20200223861A1 (en) 2020-07-16
KR20250070131A (ko) 2025-05-20
PT3665176T (pt) 2024-03-13
MX2020001547A (es) 2020-08-03
IL272556A (en) 2020-03-31
US20220009939A1 (en) 2022-01-13
MX2024003249A (es) 2024-04-04
CN111247153A (zh) 2020-06-05
JP2026012715A (ja) 2026-01-27
CA3072240A1 (en) 2019-02-14
IL313800A (en) 2024-08-01
US20250115616A1 (en) 2025-04-10
EP3665176A1 (en) 2020-06-17
MX2023005875A (es) 2023-06-05
AU2023201059A1 (en) 2023-03-23
KR20240063198A (ko) 2024-05-09
ES2974328T3 (es) 2024-06-26
EP3665176B1 (en) 2024-01-24
CN111247153B (zh) 2024-04-02
IL272556B2 (en) 2025-01-01
BR112020002892A2 (pt) 2020-08-04
JP2020530497A (ja) 2020-10-22
AU2025202936A1 (en) 2025-05-15
JP2023156372A (ja) 2023-10-24
JP7424639B2 (ja) 2024-01-30
JP7778750B2 (ja) 2025-12-02
AU2018313259B2 (en) 2022-11-24
AU2018313259A1 (en) 2020-02-27
AU2023201059B2 (en) 2025-04-03
PL3665176T3 (pl) 2024-06-17
US12145943B2 (en) 2024-11-19
KR20200040799A (ko) 2020-04-20
FI3665176T3 (fi) 2024-03-20
KR102700883B1 (ko) 2024-09-02
IL272556B1 (en) 2024-09-01

Similar Documents

Publication Publication Date Title
JP7778750B2 (ja) 3-(5-フルオロベンゾフラン-3-イル)-4-(5-メチル-5H-[1,3]ジオキソロ[4,5-f]インドール-7-イル)ピロール-2,5-ジオンの固体形態
WO2020224626A9 (zh) 用作激酶抑制剂的化合物及其应用
US20250115615A1 (en) Solid Forms of 3-(5-Fluorobenzofuran-3-yl)-4-(5-methyl-5H-[1,3]dioxolo[4,5-f]indol-7-yl)pyrrole-2,5-dione
CN105294717B (zh) 一种egfr抑制剂的盐、晶型及其用途
WO2022017478A1 (zh) 一种环己烷甲酰胺的新晶型及其制备方法
JP7054528B2 (ja) プロテインキナーゼ活性を抑制する化合物の結晶形態、及びその適用
HK40106022A (en) Solid forms of 9-ing-41
JPWO2004020433A1 (ja) 新規結晶
HK40108981A (en) Solid forms of salts of 4-[5-[(3s)-3-aminopyrrolidine-1-carbonyl]-2-[2-fluoro-4-(2-hydroxy-2-ethylpropyl)phenyl]phenyl]-2-fluoro-benzonitrile
WO2022144042A1 (zh) Tas-116的晶型及其制备方法、药物组合物和用途
WO2022143897A1 (zh) A-失碳-5α雄甾烷化合物的多晶型物
WO2019001551A1 (zh) 一种咪唑并异吲哚类衍生物游离碱的晶型及其制备方法
BR122025019554A2 (pt) Forma sólida de 3-(5-flúor-benzofuran-3-il)-4-(5-metil-5h-[1,3]dioxolo[4,5- f]indol-7-il)pirrol-2,5-diona, seus usos, composição farmacêutica e processo para preparar a mesma
CN105461698A (zh) 西地尼布盐及其晶型、以及其制备方法和药物组合物

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 40106022

Country of ref document: HK

WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20240109

WD01 Invention patent application deemed withdrawn after publication